Based on these premises, the open-label, multicenter, FIGHT-202 trial tested pemigatinib in pretreated CCA patients harboring FGFR2 gene fusions or rearrangements (n = 107), other FGFR aberrations (n = 20), or without FGFR aberrations (n = 18) (NCT02924376) [77]. Here, FGFR2 is linked to cholangiocarcinoma.